Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the USA / NCT07859709
Starting soon Observational

The CLASP III TR CED Study

NCT07859709 · tracked via the Priya Life Science USA tracker
Sponsor
Edwards Lifesciences
Phase
Observational
Started
2026-10-15
Last updated
2026-10-06

Condition(s) studied

Tricuspid RegurgitationHeart Valve DiseasesHeart DiseasesCardiovascular DiseasesTricuspid Valve Insufficiency

Investigational drug(s) / intervention(s)

PASCAL Precision system TreatedMedicare Eligible Untreated Patients

PASCAL Precision system Treated: Patients 65 years old or older with at least severe Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Repair with the PASCAL Precision system.

Medicare Eligible Untreated Patients: Patients 65 years old or older with at least severe Tricuspid Regurgitation who did not receive any transcatheter or surgical tricuspid valve intervention.

Study summary

This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Repair procedure using the PASCAL Precision system.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Medicare eligible patients, 65 years old or older * With at least severe Tricuspid Regurgitation who have either received PASCAL Precision system or been managed medically with no transcatheter or surgical tricuspid valve intervention Exclusion Criteria: * Patients not eligible for Medicare (i.e., under 65 years old) * Patients with less than severe Tricuspid Regurgitation * Patients who have received a transcatheter or surgical intervention other than PASCAL Precision system

Primary outcome measure(s)

  • Composite (All-Cause Death or Heart Failure Hospitalization) — 2 years
    Time to death or heart failure hospitalization after time zero

Trial sites (1)

FacilityCityRegionStatus
Edwards Lifesciences Irvine California

More Edwards Lifesciences trials in the USA

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis Active, not recruiting
TRISCEND II Pivotal Trial Active, not recruiting
COMPASSION S3 Post-Approval Study Active, not recruiting
Autus Valve Continued Access Study (CAS) Active, not recruiting
Autus Valve Pivotal Study Active, not recruiting

Other trials for the same condition

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation Recruiting
Trisol System EFS Study Recruiting
RADIANCE Continued Access Protocol Active, not recruiting
TRISCEND II Pivotal Trial Active, not recruiting
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07859709 on ClinicalTrials.gov ↗ ← All trials in the USA